 |
18 Diseases |  |
3 Trials |
|
3 Trials |  |
118 News |  |
| «12 |
- | Journal: Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. (Pubmed Central) - Nov 10, 2017
From a Belgian payer perspective, PP with pegfilgrastim appears cost effective compared to other prophylaxis strategies in patients with stage II breast cancer or NHL at a €30,000/QALY threshold.
- | Lonquex (lipegfilgrastim biosimilar) / Teva
Enrollment open, Trial initiation date: Lonquek for Autologous Stem Cell Mobilization (clinicaltrials.gov) - Oct 17, 2017
P1/2, N=24, Recruiting, Sponsor: Sheba Medical Center
From a Belgian payer perspective, PP with pegfilgrastim appears cost effective compared to other prophylaxis strategies in patients with stage II breast cancer or NHL at a €30,000/QALY threshold. Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Jul 2017
- ||||| Lonquex (lipegfilgrastim biosimilar) / Teva
Enrollment closed: A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia (clinicaltrials.gov) - Aug 31, 2017
P3, N=101, Active, not recruiting, Sponsor: Merckle GmbH
Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Jul 2017 Recruiting --> Active, not recruiting
- Lonquex (lipegfilgrastim biosimilar) / Teva
Enrollment closed: Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer (clinicaltrials.gov) - Jul 25, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: Beaumont Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Lonquex (lipegfilgrastim biosimilar) / Teva
Trial initiation date, Trial primary completion date: Lonquek for Autologous Stem Cell Mobilization (clinicaltrials.gov) - Apr 20, 2016
P1/2, N=24, Not yet recruiting, Sponsor: Sheba Medical Center
Recruiting --> Active, not recruiting Initiation date: Jan 2016 --> Jul 2016 | Trial primary completion date: Jan 2018 --> Jul 2018
- |||| Lonquex (lipegfilgrastim biosimilar) / Teva
Trial primary completion date: A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia (clinicaltrials.gov) - Mar 4, 2016
P3, N=100, Recruiting, Sponsor: Merckle GmbH
Initiation date: Jan 2016 --> Jul 2016 | Trial primary completion date: Jan 2018 --> Jul 2018 Trial primary completion date: Mar 2017 --> Oct 2017
- |||| Lonquex (lipegfilgrastim biosimilar) / Teva
Trial primary completion date: A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia (clinicaltrials.gov) - Jan 17, 2016
P3, N=100, Recruiting, Sponsor: Merckle GmbH
Trial primary completion date: Mar 2017 --> Oct 2017 Trial primary completion date: May 2016 --> Mar 2017
- Lonquex (lipegfilgrastim biosimilar) / Teva
Trial initiation date, Trial primary completion date: Lonquek for Autologous Stem Cell Mobilization (clinicaltrials.gov) - Dec 3, 2015
P1/2, N=24, Not yet recruiting, Sponsor: Sheba Medical Center
Trial primary completion date: May 2016 --> Mar 2017 Initiation date: Jul 2015 --> Jan 2016 | Trial primary completion date: Mar 2017 --> Jan 2018
- Lonquex (lipegfilgrastim biosimilar) / Teva
New trial: Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=40, Recruiting, Sponsor: Beaumont Hospital
- Lonquex (lipegfilgrastim biosimilar) / Teva
New P1/2 trial: Lonquek for Autologous Stem Cell Mobilization (clinicaltrials.gov) - Jul 2, 2015
P1/2, N=24, Not yet recruiting, Sponsor: Sheba Medical Center
- | Lonquex (lipegfilgrastim biosimilar) / Teva
Trial completion, Enrollment change: PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants (clinicaltrials.gov) - Jun 3, 2015
P1, N=48, Completed, Sponsor: Merckle GmbH
Initiation date: Jul 2015 --> Jan 2016 | Trial primary completion date: Mar 2017 --> Jan 2018 Active, not recruiting --> Completed | N=24 --> 48
- Lonquex (lipegfilgrastim biosimilar) / Teva
Enrollment closed: PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants (clinicaltrials.gov) - Apr 30, 2015
P1, N=24, Active, not recruiting, Sponsor: Merckle GmbH
Active, not recruiting --> Completed | N=24 --> 48 Recruiting --> Active, not recruiting
- ||||| Lonquex (lipegfilgrastim biosimilar) / Teva
Enrollment change: A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia (clinicaltrials.gov) - Apr 19, 2015
P3, N=100, Recruiting, Sponsor: Merckle GmbH
Recruiting --> Active, not recruiting N=150 --> 100
- Lonquex (lipegfilgrastim biosimilar) / Teva
Enrollment change: PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants (clinicaltrials.gov) - Apr 14, 2015
P1, N=24, Recruiting, Sponsor: Merckle GmbH
N=150 --> 100 N=48 --> 24
- | Lonquex (lipegfilgrastim biosimilar) / Teva
New P1 trial: PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants (clinicaltrials.gov) - Dec 7, 2014
P1, N=48, Recruiting, Sponsor: Merckle GmbH
- | Lonquex (lipegfilgrastim biosimilar) / Teva
Trial completion: PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma (clinicaltrials.gov) - Aug 1, 2014
P1, N=21, Completed, Sponsor: Merckle GmbH
N=48 --> 24 Active, not recruiting --> Completed
- Lonquex (lipegfilgrastim biosimilar) / Teva
Enrollment closed: PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma (clinicaltrials.gov) - May 19, 2014
P1, N=21, Active, not recruiting, Sponsor: Merckle GmbH
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||| Lonquex (lipegfilgrastim biosimilar) / Teva
Enrollment open: A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia (clinicaltrials.gov) - Feb 5, 2014
P3, N=150, Recruiting, Sponsor: Merckle GmbH
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Lonquex (lipegfilgrastim biosimilar) / Teva
New P3 trial: A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia (clinicaltrials.gov) - Jan 21, 2014
P3, N=150, Recruiting, Sponsor: Merckle GmbH
- | Lonquex (lipegfilgrastim biosimilar) / Teva
New P1 trial: PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma (clinicaltrials.gov) - Apr 24, 2012
P1, N=21, Recruiting, Sponsor: Merckle GmbH